The risk for preterm birth among women with type 1 diabetes increases considerably with increasing glycated hemoglobin levels around the time of conception, study findings indicate.
Nephrologist and Endocrinologist Katherine Tuttle joins Primary Care Physician Jay Shubrook to share best practice tips for kidney disease screening in patients with diabetes (8:16).
Escalating obesity prevalence and severity has led to type 2 diabetes being diagnosed in ever-younger people, including children. medwireNews rounds up the accumulating evidence suggesting a particularly severe diabetes course in these young people.
Escalating obesity prevalence and severity has led to type 2 diabetes being diagnosed in ever-younger people, including children. medwireNews rounds up the accumulating evidence suggesting a particularly severe diabetes course in these young people.
Editorial board member Jay Shubrook explains how the aggressive course of young-onset type 2 diabetes affects clinical decision-making for primary care providers.
The risk for preterm birth among women with type 1 diabetes increases considerably with increasing glycated hemoglobin levels around the time of conception, study findings indicate.
Fifteen years of follow-up of the DPP trial shows that although people initially lost more weight with the intensive lifestyle intervention, those assigned to metformin did better at keeping the weight off in the long term.
Men with benign prostatic hyperplasia undergoing long-term treatment with 5α-reductase inhibitors are significantly more likely to develop type 2 diabetes than those receiving the α-blocker tamsulosin, population-based study data show.
A large proportion of mobile apps for self-management of blood glucose do not provide real-time decision support for users with type 2 diabetes, researchers report.
Findings from the CREDENCE trial indicate that the SGLT2 inhibitor canagliflozin reduces the risk for renal failure and cardiovascular disease among individuals with type 2 diabetes and albuminuric chronic kidney disease.
In this video interview, diabetes specialist John Wilding discusses how the CREDENCE trial findings may impact the treatment of people with type 2 diabetes and chronic kidney disease (3:31).
Lead investigator Vlado Perkovic talks about the main findings from the CREDENCE trial – demonstrating that canagliflozin is associated with a reduced risk for kidney failure and cardiovascular events in people with type 2 diabetes and chronic kidney disease – and discusses how these results will impact clinical practice (6:51).
Adding the glucagon-like peptide-1 analog semaglutide to an existing sodium-glucose cotransporter 2 inhibitor improves glycemic control and bodyweight in patients with poorly controlled type 2 diabetes, SUSTAIN 9 data show.
